{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:31:40Z","timestamp":1792445500019,"version":"4.5.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T00:00:00Z","timestamp":1435104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0131241","type":"journal-article","created":{"date-parts":[[2015,6,24]],"date-time":"2015-06-24T18:32:51Z","timestamp":1435170771000},"page":"e0131241","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":60,"title":["Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity against Breast Cancer Models Resistant to Anti-HER2 Drugs"],"prefix":"10.1371","volume":"10","author":[{"given":"Adriana","family":"Blancafort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Gir\u00f3-Perafita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gl\u00f2ria","family":"Oliveras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f2nia","family":"Palomeras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Turrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d2scar","family":"Campuzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolors","family":"Carri\u00f3n-Salip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Massaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Brugada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Palafox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"G\u00f3mez-Miragaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Su\u00e1rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Puig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,6,24]]},"reference":[{"issue":"7","key":"ref1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrc2656","article-title":"Novel anticancer targets: revisiting ERBB2 and discovering ERBB3","volume":"9","author":"J Baselga","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"13","key":"ref2","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"MA Olayioye","year":"2000","journal-title":"EMBO J"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1097-2765(03)00047-9","article-title":"EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization","volume":"11","author":"KM Ferguson","year":"2003","journal-title":"Mol Cell"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nrm1962","article-title":"EGF-ERBB signalling: towards the systems level","volume":"7","author":"A Citri","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"ref5","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1172\/JCI32278","article-title":"ErbB receptors: from oncogenes to targeted cancer therapies","volume":"117","author":"H Zhang","year":"2007","journal-title":"J Clin Invest"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ccr.2009.03.020","article-title":"Ligand-independent HER2\/HER3\/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941","volume":"15","author":"TT Junttila","year":"2009","journal-title":"Cancer Cell"},{"issue":"26","key":"ref7","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"CE Geyer","year":"2006","journal-title":"N Engl J Med"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"M Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"ref9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/ncponc0509","article-title":"Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer","volume":"3","author":"R Nahta","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"ref10","doi-asserted-by":"crossref","first-page":"R121","DOI":"10.1186\/bcr3067","article-title":"Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers\u2014role of estrogen receptor and HER2 reactivation","volume":"13","author":"YC Wang","year":"2011","journal-title":"Breast Cancer Res"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrclinonc.2009.216","article-title":"Molecular predictors of response to trastuzumab and lapatinib in breast cancer","volume":"7","author":"FJ Esteva","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"issue":"23","key":"ref12","doi-asserted-by":"crossref","first-page":"7381","DOI":"10.1158\/1078-0432.CCR-09-1735","article-title":"Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes","volume":"15","author":"EA Mittendorf","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"9","key":"ref13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2165\/11634000-000000000-00000","article-title":"Overcoming treatment resistance in HER2-positive breast cancer: potential strategies","volume":"72","author":"F Puglisi","year":"2012","journal-title":"Drugs"},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","article-title":"PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients","volume":"6","author":"Y Nagata","year":"2004","journal-title":"Cancer Cell"},{"issue":"22","key":"ref15","doi-asserted-by":"crossref","first-page":"9221","DOI":"10.1158\/0008-5472.CAN-08-1740","article-title":"Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR\/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235","volume":"68","author":"PJ Eichhorn","year":"2008","journal-title":"Cancer Res"},{"issue":"7152","key":"ref16","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nature05933","article-title":"A transforming mutation in the pleckstrin homology domain of AKT1 in cancer","volume":"448","author":"JD Carpten","year":"2007","journal-title":"Nature"},{"issue":"5765","key":"ref17","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1126\/science.1123248","article-title":"Architecture of mammalian fatty acid synthase at 4.5 A resolution","volume":"311","author":"T Maier","year":"2006","journal-title":"Science"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10549-007-9678-5","article-title":"Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75","volume":"109","author":"T Puig","year":"2008","journal-title":"Breast Cancer Res Treat"},{"issue":"24","key":"ref19","doi-asserted-by":"crossref","first-page":"7608","DOI":"10.1158\/1078-0432.CCR-09-0856","article-title":"Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity","volume":"15","author":"T Puig","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.bbrc.2009.05.085","article-title":"Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells","volume":"385","author":"TW Grunt","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"7","key":"ref21","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/jnci\/djp030","article-title":"Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer","volume":"101","author":"T Migita","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1177\/011542650702200174","article-title":"Modulation of lipid rafts by Omega-3 fatty acids in inflammation and cancer: implications for use of lipids during nutrition support","volume":"22","author":"RA Siddiqui","year":"2007","journal-title":"Nutr Clin Pract"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"e5877","DOI":"10.1371\/journal.pone.0005877","article-title":"p63 promotes cell survival through fatty acid synthase","volume":"4","author":"V Sabbisetti","year":"2009","journal-title":"PLoS One"},{"issue":"5475","key":"ref24","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1126\/science.288.5475.2379","article-title":"Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors","volume":"288","author":"TM Loftus","year":"2000","journal-title":"Science"},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"R352","DOI":"10.1152\/ajpregu.00862.2006","article-title":"Pharmacological stimulation of brain carnitine palmitoyl-transferase-1 decreases food intake and body weight","volume":"294","author":"S Aja","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1002\/cncr.11200","article-title":"A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma","volume":"97","author":"A Jatoi","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"230S","DOI":"10.1093\/ajcn\/81.1.230S","article-title":"Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies","volume":"81","author":"C Manach","year":"2005","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"ref28","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1021\/jm2016045","article-title":"New synthetic inhibitors of fatty acid synthase with anticancer activity","volume":"55","author":"C Turrado","year":"2012","journal-title":"J Med Chem"},{"issue":"6","key":"ref29","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/bcr3077","article-title":"A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines","volume":"13","author":"T Puig","year":"2011","journal-title":"Breast Cancer Res"},{"key":"ref30","first-page":"33","article-title":"Human breast cancer in culture","volume":"57","author":"GL Trempe","year":"1976","journal-title":"Recent Results Cancer Res"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s00280-003-0728-3","article-title":"In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells","volume":"53","author":"R Nahta","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1749-6632.2010.05777.x","article-title":"Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer","volume":"1210","author":"G Oliveras","year":"2010","journal-title":"Ann N Y Acad Sci"},{"issue":"4785","key":"ref33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"DJ Slamon","year":"1987","journal-title":"Science"},{"issue":"4905","key":"ref34","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"DJ Slamon","year":"1989","journal-title":"Science"},{"issue":"3","key":"ref35","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2174\/1568009023333872","article-title":"Examining the relationship between cancer invasion\/metastasis and drug resistance","volume":"2","author":"Y Liang","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"key":"ref36","first-page":"21","article-title":"Drug Resistance in Cancer Cells","author":"D Fan","year":"2009"},{"issue":"6A","key":"ref37","first-page":"3671","article-title":"Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals","volume":"28","author":"T Puig","year":"2008","journal-title":"Anticancer Res"},{"issue":"3","key":"ref38","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-009-0592-x","article-title":"EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance","volume":"122","author":"R Dua","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"ref39","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","article-title":"Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network","volume":"13","author":"CA Ritter","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-010-1200-9","article-title":"High serum TGF-\u03b1 predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer","volume":"125","author":"J Rhee","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref41","unstructured":"A B, T P, inventors; P201231228, assignee. Trastuzumab and lapatinib-resistant cell lines as an screening method for testing the drug antitumor activity in this setting2013."},{"issue":"4","key":"ref42","doi-asserted-by":"crossref","first-page":"R50","DOI":"10.1186\/bcr2339","article-title":"Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer","volume":"11","author":"A Sassen","year":"2009","journal-title":"Breast Cancer Res"},{"issue":"3","key":"ref43","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.3892\/ijo.2012.1509","article-title":"Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands","volume":"41","author":"D Carri\u00f3n-Salip","year":"2012","journal-title":"Int J Oncol"},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","article-title":"A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer","volume":"12","author":"K Berns","year":"2007","journal-title":"Cancer Cell"},{"issue":"2","key":"ref45","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2174\/156800910791054211","article-title":"Ras-induced resistance to lapatinib is overcome by MEK inhibition","volume":"10","author":"G Zoppoli","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"issue":"2","key":"ref46","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.3390\/ijms13021886","article-title":"The mTOR Signalling Pathway in Human Cancer","volume":"13","author":"H P\u00f3pulo","year":"2012","journal-title":"Int J Mol Sci"},{"issue":"39","key":"ref47","doi-asserted-by":"crossref","first-page":"37288","DOI":"10.1074\/jbc.M303257200","article-title":"Inactivation of the tuberous sclerosis complex-1 and -2 gene products occurs by phosphoinositide 3-kinase\/Akt-dependent and-independent phosphorylation of tuberin","volume":"278","author":"AR Tee","year":"2003","journal-title":"J Biol Chem"},{"issue":"13","key":"ref48","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1158\/1078-0432.CCR-13-2769","article-title":"Targeting PI3K\/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT","volume":"20","author":"NA O'Brien","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref49","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S1470-2045(14)70138-X","article-title":"Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"15","author":"F Andr\u00e9","year":"2014","journal-title":"Lancet Oncol"},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"e97697","DOI":"10.1371\/journal.pone.0097697","article-title":"The mTOR Inhibitor Rapamycin Synergizes with a Fatty Acid Synthase Inhibitor to Induce Cytotoxicity in ER\/HER2-Positive Breast Cancer Cells","volume":"9","author":"C Yan","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"ref51","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/jnci\/djk151","article-title":"Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy","volume":"99","author":"G Arpino","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1158\/0008-5472.CAN-03-3856","article-title":"The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells","volume":"64","author":"R Nahta","year":"2004","journal-title":"Cancer Res"},{"issue":"1","key":"ref53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.canlet.2011.06.005","article-title":"Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors","volume":"311","author":"S Gaur","year":"2011","journal-title":"Cancer Lett"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s00432-014-1628-0","article-title":"Temsirolimus and chloroquine cooperatively exhibit a potent antitumor effect against colorectal cancer cells","volume":"140","author":"M Kaneko","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"ref55","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","article-title":"Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus","volume":"66","author":"D Del Bufalo","year":"2006","journal-title":"Cancer Res"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0131241","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,8]],"date-time":"2020-05-08T21:30:47Z","timestamp":1588973447000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0131241"}},"subtitle":[],"editor":[{"given":"Ramon Andrade","family":"de Mello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,24]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0131241","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,24]]}}}